Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting-Reference-Cited by-同舟云学术

Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting

Published:2020-08-18 Issue:19 Volume:63 Page:10879-10896
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Huard Kim¹,Smith Aaron C.²^ORCID,Cappon Gregg²,Dow Robert L.¹^ORCID,Edmonds David J.¹^ORCID,El-Kattan Ayman¹,Esler William P.¹,Fernando Dilinie P.²,Griffith David A.¹,Kalgutkar Amit S.¹^ORCID,Ross Trenton T.¹,Bagley Scott W.²^ORCID,Beebe David¹,Bi Yi-An²,Cabral Shawn²,Crowley Collin¹,Doran Shawn D.²,Dowling Matthew S.²^ORCID,Liras Spiros¹^ORCID,Mascitti Vincent²,Niosi Mark²,Pfefferkorn Jeffrey A.¹,Polivkova Jana²,Préville Cathy²,Price David A.¹,Shavnya Andre²,Shirai Norimitsu²,Smith Andrew H.²,Southers James R.²,Tess David A.¹,Thuma Benjamin A.²,Varma Manthena V.²^ORCID,Yang Xiaojing²

Affiliation:

1. Pfizer Worldwide Research and Development, 1 Portland Street, Cambridge, Massachusetts 02139, United States

2. Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c00640

Reference55 articles.

1. Malonyl-CoA, a Key Signaling Molecule in Mammalian Cells

2. Isozyme-nonselective N-Substituted Bipiperidylcarboxamide Acetyl-CoA Carboxylase Inhibitors Reduce Tissue Malonyl-CoA Concentrations, Inhibit Fatty Acid Synthesis, and Increase Fatty Acid Oxidation in Cultured Cells and in Experimental Animals